Progress in cancer screening: Where are we in 2014?

Cancer Forum

Volumn 38, Issue 3, 2014, Pages 191-196

  Canfell, Karen ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b Cancer Council Australia   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MOLECULAR MARKER; PROSTATE SPECIFIC ANTIGEN; WART VIRUS VACCINE;

AUSTRALIA; BREAST CANCER; CANCER PREVENTION; CANCER SCREENING; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIGITAL MAMMOGRAPHY; HEALTH CARE POLICY; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; INTESTINE CANCER; LUNG CANCER; MOUTH CANCER; OCCULT BLOOD TEST; PAPANICOLAOU TEST; PRACTICE GUIDELINE; REVIEW; TRANSVAGINAL ECHOGRAPHY; UTERINE CERVIX CANCER; VACCINATION;

EID: 84916634489     PISSN: 0311306X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Andermann A, Blancquaert I, Beauchamp S, et al. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bulletin of the World Health Organization. 2008; 86:241-320.
2. Australian Population Health Development Principal Committee. Population Based Screening Framework: Australian Health Ministers' Advisory Council; 2008.
3. Roder D. Breast Cancer Screening: Update in the Australian context. Cancer Forum. 2014;38(3) 197-198
4. Patnick J. Breast Cancer Screening: The UK Independent Review and update on breast screening in England. Cancer Forum. 2014;38(3) 199-202
5. Evaluating the Age Extension of the NHS Breast Screening Programme. (Accessed 23 September, 2014,, at http://clinicaltrials.gov.)
6. Smith MA. Update on HPV vaccination in Australia. Cancer Forum. 2014;38(3) 207-208
7. Castle P. The new era of primary HPV screening for prevention of invasive cervical cancer. Cancer Forum. 2014;38(3) 209-214
8. Ronco G, Dillner J, Elfstrom KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383:209-214
9. Saville M. Update on cervical screening. Cancer Forum. 2014;38(3) 215-217
10. Lew∗ JB, Simms∗ K, Smith M, et al. National Cervical Screening Program Renewal: Effectiveness modelling and economic evaluation in the Australian setting (Assessment Report). MSAC Application No. 1276. ∗Joint first authors 2013.
11. Young GP. Screening for colorectal cancer - new evidence in the last 10 years. Cancer Forum. 2014;38(1) 11-14.
12. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993;328:1365-71.
13. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348:1472-7.
14. Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348:1467-71.
15. Mandel JS, Church TR, Ederer F, et al. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst. 1999;91:434-7.
16. Faivre J, Dancourt V, Lejeune C, et al. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology. 2004;126:1674-80.
17. van Rossum LG, van Rijn AF, Laheij RJ, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology. 2008;135:82-90.
18. Tran B, Keating CL, Ananda SS, et al. Preliminary analysis of the cost-effectiveness of the National Bowel Cancer Screening Program: demonstrating the potential value of comprehensive real world data. Internal medicine journal. 2012;42:794-800.
19. Pignone MP, Flitcroft KL, Howard K, et al. Costs and cost-effectiveness of full implementation of a biennial faecal occult blood test screening program for bowel cancer in Australia. Med J Aust. 2011;194:180-5.
20. Bowel (colorectal) cancer. 2014. (Accessed September 23, 2014, , at http://wiki.cancer.org.au/policy/Bowel-cancer/Screening#Screening-for-bowel-cancer.)
21. Australian Cancer Network Colorectal Cancer Guidelines Revision Committee. Guidelines for the Prevention, Early Detection and Management of Colorectal Cancer. Sydney: The Cancer Council Australia and Australian Cancer Network; 2005.
22. Australian Institute of Health and Welfare. National Bowel Cancer Screening Program monitoring report: 2012-2013. Canberra: AIHW; 2014.
23. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370:1287-97.
24. Church TR, Wandell M, Lofton-Day C, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 2014;63:317-25.
25. Bryant H. Of babies and bathwater: Reconsidering the public health approach to breast cancer screening. Cancer Forum. 2014;38(3) 202-206
26. IARC Handbooks of Cancer Prevention. 2014. (Accessed September 23, 2014, at http://www.iarc.fr/en/meetings/handbooks/index.php.)
27. Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012;366:981-90.
28. Andriole GL, Crawford ED, Grubb RL, 3rd, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104:125-32.
29. Armstrong B, Lowe A. Clinical practice guidelines for PSA testing and early management of test-detected prostate cancer. Cancer Forum. 2014;38(3) 218-220
30. Thompson IM, Jr., Leach RJ, Ankerst DP. Focusing PSA testing on detection of high-risk prostate cancers by incorporating patient preferences into decision making. JAMA. 2014;312:995-6.
31. Caruana M, Jung-Kang Y, Smith D, et al. Estimating the benefits and harms of PSA testing in Australian context. Cancer Forum. 2014;38(3) 221-223
32. Application No. 1276 - Renewal of the National Cervical Screening Program. 2014. at http://www.msac.gov.au/internet/msac/publishing.nsf/Content/FD36D6990FFAA639CA25799200058940/$File/1276%20-%20Final%20MSAC%20PSD%20-%20NCSP%20Renewal.pdf.)
33. Robotin MC, Kansil MQ, Porwal M, et al. Community-based prevention of hepatitis-B-related liver cancer: Australian insights. Bulletin of the World Health Organization 2014;92:309-84.
34. Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009;10:327-40.
35. Australian Institute of Health, Welfare & Cancer Australia. Lung cancer in Australia: an overview. Cancer series no. 64. Cat. no. CAN 58. Canberra: AIHW; 2011.
36. Moyer VA. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160:330-8.
37. Brawley O. Lung cancer screening: Summary of the evidence and the 2013 US Preventative Services Taskforce recommendations. Cancer Forum. 2014;38(3) 224-226
38. Screening Section, Department of Health and Ageing. Lung Cancer Screening - Overview of the evidence and issues. 2013.
39. Marshall HM, Bowman RV, Crossin J, et al. Queensland Lung Cancer Screening Study: rationale, design and methods. Internal medicine journal. 2013;43:174-82.
40. Patz EF, Jr., Pinsky P, Kramer BS. Estimating overdiagnosis in lung cancer screening - reply. JAMA internal medicine. 2014;174:1198-9.
41. de Koning HJ, Meza R, Plevritis SK, et al. Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. Ann Intern Med 2014;160:311-20.
42. Tammemagi MC, Mayo JR, Lam S. Cancer in pulmonary nodules detected on first screening CT. N Engl J Med. 2013;369:2060-1.
43. Logan R. Oral cancer screening. Cancer Forum. Cancer Forum. 2014;38(3) 227-229
44. Olson CM, Burda BU, Beil T, et al. Screening for Oral Cancer: A Targeted Evidence Update for the U.S. Preventive Services Task Force. Rockville MD 2013.
45. Sankaranarayanan R, Ramadas K, Thomas G, et al. Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial. Lancet. 2005;365:1927-33.
46. Dedhia RC, Smith KJ, Johnson JT, et al. The cost-effectiveness of community-based screening for oral cancer in high-risk males in the United States: A Markov decision analysis approach. The Laryngoscope. 2011;121:952-60.
47. Health S. Aboriginal and Torres Strait Islander Companion Document to the Statewide Cancer Control Plan (2011-2015). Adelaide, SA Health; 2011.
48. Frayling I, Ward R. Should we consider introducing systematic screening for Lynch Syndrome? Cancer Forum. 2014;38(3) 229-232